EUVIMEDAtrasti EUVIMED
Crossref

A critical evidence-based summary of the use of beta-blockers in stable coronary artery disease

Andrea Lynn Cartwright, Kyle John Wilby

Avicenna · 2014

DOI: 10.5339/avi.2014.4 ↗

At a glance

Journal article in Avicenna, 2014. Written by Andrea Lynn Cartwright and 1 co-authors. 10 references.

SantraukaBibliografiniai duomenysCiteRelated studies

Abstract (original language)

Current clinical recommendations for patients with stable coronary artery disease (CAD) and those post-acute coronary syndromes (ACS) suggest initiation of patients on dual antiplatelet therapy, an angiotensin-converting enzyme (ACE) inhibitor, a beta-blocker and an HMG-CoA reductase inhibitor prior to hospital discharge. Commonly, this drug regimen is continued indefinitely. More recently, however, emerging evidence suggests that long-term therapy with beta-blockers may in fact be of no benefit to patients with stable CAD. This evidence-based review will summarize the current practice recommendations, as well as provide a critical analysis of available literature regarding beta-blockers in stable CAD. Both efficacy and safety will be considered and implications for current clinical practice will be discussed.

Cite

APA

Cartwright, A. L., & Wilby, K. J. (2014). A critical evidence-based summary of the use of beta-blockers in stable coronary artery disease. Avicenna. https://doi.org/10.5339/avi.2014.4

Vancouver

Cartwright AL, Wilby KJ. A critical evidence-based summary of the use of beta-blockers in stable coronary artery disease. Avicenna. 2014. doi:10.5339/avi.2014.4

BibTeX
@article{Cartwright2014,
  author = {Cartwright, Andrea Lynn and Wilby, Kyle John},
  title = {A critical evidence-based summary of the use of beta-blockers in stable coronary artery disease},
  journal = {Avicenna},
  year = {2014},
  doi = {10.5339/avi.2014.4}
}
Start for free →